Press Release

09th July, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Semalix Injection Disposable Pens – Update A press release issued by the Company with respect to captioned subject is attached for your information and record. Thanking you, Yours sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN TRIVEDI COMPANY SECRETARY Encl: A/a Email – investorservices@torrentpharma.com Semalix Injection Disposable Pens – Update Ahmedabad, 9th July 2026: Torrent Pharmaceuticals Limited (Torrent) is implementing a voluntary recall as a precautionary measure only for select batches of Semalix injection disposable pens. This action follows a product recall notification issued by our manufacturer Dr. Reddy's Laboratories Ltd., Hyderabad (DRL), for a technical evaluation. Patient safety is of paramount importance to us. There is no risk to patients already on this treatment because of this recall. Further, all other SKUs of Semaglutide being sold by Torrent including the oral formulation remain completely unaffected. Affected Products:  Semalix Injection (select batches of 2 mg & 4 mg, manufactured by DRL) Unaffected Products:  Semalix tablet 3 mg, 7 mg, 14 mg (manufactured by Torrent)  Sembolic tablet 3 mg, 7 mg, 14 mg (manufactured by Torrent)  Semalix injection 8 mg (manufactured by MSN Laboratories)  Sembolic re-usable injection (manufactured by Zydus Lifesciences Ltd.) If you or your family members are currently treated by any of the above products, please reach out to pv@torrentpharma.com for any further clarification you may require.